Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.42 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | APEX1 | P27695 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 2/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13520471 | 0.83 | GRM2 (0.50) | HPGDKDM4ERIPK1FFAR1GRM2 | |
| SCHEMBL23430239 | 0.82 | HPGD (0.46) | HPGDBLMKDM4ERIPK1CTBP2 | |
| SCHEMBL5394972 | 0.82 | PPARG (0.49) | HPGDBLMKDM4ERIPK1CTBP2 | |
| SCHEMBL13809480 | 0.82 | BLM (0.65) | HPGDBLMKDM4EPOLBAPEX1 | |
| SCHEMBL180161 | 0.82 | SMN1; SMN2 (0.55) | BLM | |
| SCHEMBL1275761 | 0.82 | SMN1; SMN2 (0.55) | BLM | |
| SCHEMBL3361395 | 0.82 | SMN1; SMN2 (0.55) | BLM | |
| SCHEMBL2175090 | 0.81 | BLM (0.44) | HPGDBLMKDM4EPOLBAPEX1 | |
| SCHEMBL2175094 | 0.81 | BLM (0.44) | HPGDBLMKDM4EPOLBAPEX1 | |
| SCHEMBL28417924 | 0.80 | CTBP2 (0.43) | HPGDBLMKDM4ECTBP2FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645898-B2 | Selective androgen receptor modulators and method of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2010-01-12 | — | — | US | disclosed |
| US-7645898-B2 | Selective androgen receptor modulators and method of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2010-01-12 | — | — | US | disclosed |
| EP-1954263-A2 | COMPOSITION FOR INCREASING STEADY STATE PLASMA LEVELS OF BICALUTAMIDE | AstraZeneca AB (SE) | 2008-08-13 | — | — | EP | disclosed |
| US-20080161404-A1 | Bicalutamide for Delivering Increasing Steady State Plasma Levels | ASTRAZENECA AB (SE) | 2008-07-03 | — | — | US | disclosed |
| US-20070173546-A1 | Selective androgen receptor modulators and method of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2007-07-26 | — | — | US | disclosed |
| US-20070173546-A1 | Selective androgen receptor modulators and method of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2007-07-26 | — | — | US | disclosed |
| US-20070161608-A1 | Selective androgen receptor modulators for treating muscle wasting | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2007-07-12 | — | — | US | disclosed |
| US-20070161608-A1 | Selective androgen receptor modulators for treating muscle wasting | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2007-07-12 | — | — | US | disclosed |
| US-20070123563-A1 | Selective androgen receptor modulators and method of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2007-05-31 | — | — | US | disclosed |
| US-20070123563-A1 | Selective androgen receptor modulators and method of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2007-05-31 | — | — | US | disclosed |
| WO-2003097035-A1 | NON-STEROIDAL ANTI-ANDROGEN THERAPY | ASTRAZENECA UK LIMITED (GB) | 2003-11-27 | — | — | WO | disclosed |
| US-6593492-B1 | Reacting hydroxyalkylcarboxylic acid derivative with cinchonidine; salt formation; contact with methylene chloride and diethyl ether solvent; acylation, amidation | NOBEX CORPORATION | 2003-07-15 | — | — | US | disclosed |
| WO-2003043606-A1 | PHARMACEUTICAL FORMULATION COMPRISING BICALUTAMIDE | ASTRAZENECA UK LIMITED (GB) | 2003-05-30 | — | — | WO | disclosed |
| WO-2003043630-A1 | SOLID PHARMACEUTICAL COMPOSITION COMPRISING 4-CYANO-TRIFLUORO-3-(4-FLUOROPHENYL SULPHONYL)-2-HYDROXY-2-METHYLPROPIONO- M TOLUIDIDE, PVP, AN ANTI-OESTROGEN AND/OR AN AROMATASE INHIBITOR | ASTRAZENECA UK LIMITED (GB) | 2003-05-30 | — | — | WO | disclosed |
| WO-2003032950-A1 | PHARMACEUTICAL FORMULATION COMPRISING (R) -BICALUTAMIDE | ASTRAZENECA AB (SE) | 2003-04-24 | — | — | WO | disclosed |
| CN-1413188-A | Resolution of intermediates in synthesis of substantially pure bicalutamide | NOBEX CORP (US) | 2003-04-23 | — | — | CN | disclosed |
| WO-2002080902-A1 | SOLID PHARMACEUTICAL COMPOSITION COMPRISING 4 -CYANO-TRIFLUORO-3-(4-FLUOROPHENYLSULPHONYL)-2-HYDROXY-2-METHYLPROPIONO- M TOLUIDIDE AND PVP | ASTRAZENECA AB (SE) | 2002-10-17 | — | — | WO | disclosed |
| EP-1224167-A1 | RESOLUTION OF INTERMEDIATES IN THE SYNTHESIS OF SUBSTANTIALLY PURE BICALUTAMIDE | Nobex Corporation (US) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001034563-A1 | RESOLUTION OF INTERMEDIATES IN THE SYNTHESIS OF SUBSTANTIALLY PURE BICALUTAMIDE | NOBEX CORPORATION (US) | 2001-05-17 | — | — | WO | disclosed |
| US-5985868-A | TREATMENT OF ANDROGEN-DEPENDENT PROSTATE CANCER; ALSO FOR TREATMENT OF BENIGN PROSTATIC HYPERTROPHY OR HYPERPLASIA, ACNE AND HIRSUTISM | SEPRACOR INC. (US) | 1999-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161404-A1 | Bicalutamide for Delivering Increasing Steady State Plasma Levels | AR, MME, SHBG | HPGD 703/4885BLM 4860/4885KDM4E 44/4885 |
| US-20070173546-A1 | Selective androgen receptor modulators and method of use thereof | AR, SHBG, ESRRA | HPGD 1141/4885BLM 4617/4885KDM4E 1076/4885 |
| US-20070123563-A1 | Selective androgen receptor modulators and method of use thereof | AR, SHBG, ESRRA | HPGD 1141/4885BLM 4617/4885KDM4E 1076/4885 |
| US-20070161608-A1 | Selective androgen receptor modulators for treating muscle wasting | AR, ESRRA, SHBG | HPGD 1872/4885BLM 4620/4885KDM4E 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.